Latest Breaking News On - Renan denoncourt - Page 1 : comparemela.com

18-Month Data for Patisiran in ATTR with Amyloidosis Consistent with Primary Results

Data from the open-label extension period of the APOLLO-B trial provide new insight into the benefits of patisiran in patients with ATTR amyloidosis with cardiomyopathy.

Czech republicRenan denoncourtMarianna fontanaInternational symposium on amyloidosisAsian society of cardiovascular imaging marianna fontanaAlnylam pharmaceuticalsDrug administrationInvestor relations alnylam pharmaceuticals incAsian societyCardiovascular imagingAnnual congressHeart failure associationEuropean societyHeart failureNew drug applicationInternational symposium

Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

– Continued Treatment with Patisiran in Open-Label Extension Period Showed Evidence of Sustained Benefit across Measures of Functional Capacity and Health Status and Quality of Life, as well as. | May 20, 2023

United statesUnited kingdomRenan denoncourtEuropean unionAlnylam pharmaceuticalsAlnylam pharmaceuticals nasdaqDrug administrationExchange commissionRenal drugs advisory committeeAlnylam pharmaceuticals incSecurities exchangeAnnual congressHeart failure associationEuropean societyHeart failureNew drug application

Patisiran Under Review for Cardiomyopathy of ATTR Amyloidosis

The FDA has accepted the sNDA for patisiran for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis.

Renan denoncourtDrug administrationNew drug applicationMinute walk testKansas city cardiomyopathy questionnaireVice presidentPrescription drug user fee act

Alnylam Announces U S Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

21.02.2023 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s supplemental New Drug Application (sNDA) for patisiran, an . Seite 1

Renan denoncourtInternational symposium on amyloidosisDrug administrationAlnylam pharmaceuticals incAlnylam pharmaceuticalsNew drug applicationPrescription drug user fee actVice presidentInternational symposiumHeart failure societyAnnual scientific

Alnylam Submits Supplemental New Drug Application (sNDA) to U S Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Alnylam Submits Supplemental New Drug Application (sNDA) to U S Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesChristine regan lindenboomJosh brodskyRenan denoncourtInternational symposium on amyloidosisDrug administrationAlnylam pharmaceuticals incHealth statusExchange commissionAlnylam pharmaceuticalsEuropean unionFunctional capacityLife comparedNew drug applicationVice president